{"id":1039538,"date":"2012-04-30T18:12:45","date_gmt":"2012-04-30T18:12:45","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/direct-flow-medical%c2%ae-announces-the-appointment-of-chief-medical-officer-charles-davidson-md.php"},"modified":"2024-08-17T16:28:22","modified_gmt":"2024-08-17T20:28:22","slug":"direct-flow-medical-announces-the-appointment-of-chief-medical-officer-charles-davidson-md","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medical-school\/direct-flow-medical-announces-the-appointment-of-chief-medical-officer-charles-davidson-md.php","title":{"rendered":"Direct Flow Medical\u00ae Announces the Appointment of Chief Medical Officer, Charles Davidson, MD"},"content":{"rendered":"<p><p>    SANTA ROSA, Calif.--(BUSINESS WIRE)--  <\/p>\n<p>    Direct Flow    Medical, Inc., a privately held, emerging medical device    company focused on the next generation, minimally invasive    implant to treat patients with heart valve disease announced    the appointment of Charles Davidson, MD, as Chief Medical    Officer. Dr. Davidson brings a wealth of knowledge to the    organization, having spent over 20 years in interventional    cardiology and medicine. He has also worked extensively    in his career with medical device industry leaders and start-up    companies.  <\/p>\n<p>    Dr. Davidson currently is a Professor of Medicine at    Northwestern University Feinberg School of Medicine and is the    Director of the Cardiac Catheterization Laboratory and Clinical    Chief of Cardiology at Northwestern Memorial Hospital, Chicago,    Illinois. His professional memberships include Fellow, American    College of Cardiology, Fellow of the Society for Cardiac    Angiography and Interventions and a Fellow membership with the    Clinical Council,    American Heart Association. Prior positions were held at    Duke University Medical Center and Yale University School of    Medicine. Dr. Davidsons experience in interventional    cardiology and his extensive knowledge of cardiac care will be    invaluable to Direct Flow Medical as we continue to expand our    clinical trials and drive the future growth of the    Company, commented Bernard Lyons, President and CEO of    Direct Flow    Medical. His longstanding thought leadership in the    care of patients with cardiac disease, experience in novel    interventional devices combined with his first-hand experience    in the transcatheter aortic valve replacement (TAVR) procedures    will help us achieve our clinical and market objectives.    Simply, this is just a terrific addition to our existing    team. The current clinical programs are actively    recruiting patients outside the United States.  <\/p>\n<p>    Dr. Davidsons connection with Direct Flow Medical began 3    years ago, when he first reviewed the early clinical data from    the feasibility study and has been a key consultant to the    DISCOVER CE Mark Study which was initiated late in 2011.    About his newest affiliation with the organization, Dr.    Davidson says, I am very impressed with the Direct Flow    Medical device. This is a true, second generation device which    is designed to allow for precise placement, conforms to the    aortic valve anatomy, thereby virtually eliminating any    paravalvular leaks. I look forward to working with the    Direct Flow Medical Team and their outstanding group of    clinical investigators and advisors to help bring this latest,    unique innovation to fruition. The Direct Flow Medical    device addresses one of the most important clinical issues in    the TAVR Market  aortic regurgitation. It has the    potential to improve clinical outcomes globally and better    serve the needs of this growing patient population.  <\/p>\n<p>    About Direct Flow Medical, Inc.  <\/p>\n<p>    Founded in 2004, the Company is headquartered in Santa Rosa,    California, and has a second technology and manufacturing    facility in Lake Forest, California. The Companys unique    implant design is not limited to aortic valve disease but is    readily applicable to mitral and other heart valve anatomical    sites. Direct Flow Medical has raised 3 rounds of funding to    date with the following investors: EDF Ventures, New Leaf    Venture Partners, Spray Venture Partners, Foundation Medical    Partners, VantagePoint Venture Partners, ePlanet Venture    Partners and strategic corporate investors. For further    information, please visit the website at     <a href=\"http:\/\/www.directflowmedical.com\" rel=\"nofollow\">http:\/\/www.directflowmedical.com<\/a>.  <\/p>\n<p>    The Direct Flow Medical Transcatheter Aortic Valve System is    an investigation device, limited by applicable law to    investigational use and not available for sale.  <\/p>\n<\/p>\n<p>Link:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/direct-flow-medical-announces-appointment-150100711.html;_ylt=A2KJ3CUT1p5PizYAW4r_wgt.\" title=\"Direct Flow Medical\u00ae Announces the Appointment of Chief Medical Officer, Charles Davidson, MD\" rel=\"noopener\">Direct Flow Medical\u00ae Announces the Appointment of Chief Medical Officer, Charles Davidson, MD<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SANTA ROSA, Calif.--(BUSINESS WIRE)-- Direct Flow Medical, Inc., a privately held, emerging medical device company focused on the next generation, minimally invasive implant to treat patients with heart valve disease announced the appointment of Charles Davidson, MD, as Chief Medical Officer. Dr. Davidson brings a wealth of knowledge to the organization, having spent over 20 years in interventional cardiology and medicine.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medical-school\/direct-flow-medical-announces-the-appointment-of-chief-medical-officer-charles-davidson-md.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[36],"tags":[],"class_list":["post-1039538","post","type-post","status-publish","format-standard","hentry","category-medical-school"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1039538"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1039538"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1039538\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1039538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1039538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1039538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}